The influence of TLR4 agonist lipopolysaccharides on hepatocellular carcinoma cells and the feasibility of its application in treating liver cancer

OncoTargets and Therapy

Volumn 8, Issue , 2015, Pages 2215-2225

  Gu, Junsheng ^a   Sun, Ranran ^a   Shen, Shen ^a   Yu, Zujiang ^a  

^a THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

Author keywords

Annexin V PI double staining; Cell proliferation; LPS; Propidium iodide single staining; Signaling pathway; Water soluble tetrazolium 1

Indexed keywords

CYCLIN D1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; INTERLEUKIN 8; LIPOPOLYSACCHARIDE; MESSENGER RNA; STAT3 PROTEIN; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA;

APOPTOSIS; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CELL; CANCER INHIBITION; CANCER RESISTANCE; CELL CYCLE REGULATION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; FEASIBILITY STUDY; HEPATOCELLULAR CARCINOMA CELL LINE; HUMAN; HUMAN CELL; LIVER CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING;

EID: 84940063312     PISSN: None     EISSN: 11786930     Source Type: Journal    
DOI: 10.2147/OTT.S86536     Document Type: Article

References (21)

1. Jia F, Zheng W. Advancements in the surgical treatment of hepatocellular carcinoma. Pract J Clin Med. 2011;8(1):16–19.
2. Chengfang Y, Qing X. Advances in research of biotherapies for primary hepatocellular carcinoma. Med Recapitulate. 2012;18(4):524–527.
3. Huajun Z, Ang L, Qiuju H, Jian Z. Influence of TLR4 signaling on polyI: C-induced apoptosis of hepatocellular carcinoma cells. Chin J Immunol. 2014;30(1):30–33.
4. Hong W, Haipeng Z, Liangjie L, Zhimin F. The influence of TLR4 on the radiosensitivity of human breast cancer cell MCF-7. Chin J Gerontol. 2014;34(11):3076–3078.
5. Lihua Z, Jun L, Namei Z, Dongtie W, Qiaoli L. Research progress of diseases and drugs related with TLR2 and TLR4. Chin J Cell Mol Immunol. 2014;30(7):767–770.
6. Yutong H, Chunhai C, Xuesen Y, Zhengping Y. Lipopolysaccharide-induced activation of microglia through JAK2-STAT3 pathway. Acta Academiae Medicinae Militaris Tertiae. 2009;31(12):1119–1122.
7. Folkert S, Takeshi K, Christian B, Dennis MK. TLR-based immune adjuvants. Vaccine. 2011;29(11):3341–3355.
8. Coffman RL, Sher A, Seder RA. Vaccine adjuvants: putting innate immunity to work. Immunity. 2010;33(4):492–503.
9. Hoebe CJ, Vermeiren AP, Dukers-Muijrers NH. Revaccination with Fendrix or HBVaxPro results in better response rates does revaccination with three doses of Engerix-B. in previous non-responders. Vaccine. 2012;30(48):6734–6737.
10. Krieg AM. Toll-like receptor 9 (TLR9) agonists in the treatment of cancer. Oncogene. 2008;27(2):161–167.
11. Szczepanski MJ, Czystowska M, Szajnik M, et al. Triggering of Toll-like receptor 4 expressed on human head and neck squamous cell carcinoma promotes tumor development and protects the tumor from immune attack. Cancer Res. 2009;69(7):3105–3113.
12. Anding G, Baoshun L, Xiaopeng L. STAT3 and tumor. Chin J Biochem Mol Biol. 2013;29(5):397–403.
13. Sheau-Fang Y, Shen-Nien W, Chih-Fung W, et al. Altered p-STAT3 (tyr705) expression is associated with histological grading and intratumour microvessel density in hepatocellular carcinoma. J Clin Pathol. 2007;60(6):642–648.
14. Xiaoxia S, Jian Z, Lihua W, Zhigang T. Growth inhibition of human hepatocellular carcinoma cells by blocking STAT3 activation with decoy-ODN. Cancer Lett. 2008;262(2):201–213.
15. Elke MB, Maciej S, Angela W, Thomas W, HW Loems ZH. Role of Stat3 in lipopolysaccharide-induced IL-10 gene expression. J Immunol. 2000;165(3):1612–1617.
16. Claire JG, Stefan RJ, Rami L, et al. IL-6 trans-signaling modulates TLR4-dependent inflammatory responses via STAT3. J Immunol. 2011;186(2):1199–1208.
17. Alexander G, Helena JMS, Amy Elizabeth M, et al. The COX-2/PGE2 pathway: key roles in the hallmarks of cancer andadaptation to the tumour microenvironment. Carcinogenesis. 2009;30(3):377–386.
18. Han C, Demetris AJ, Stolz DB, Xu L, Lim K, Wu T. Modulation of Stat3 activation by the eytosolic phospholipase Asa and cyclooxygenase-2-controlledprostaglandin E2 signaling pathway. Biol Chem. 2006;28(34): 24831–24846
19. Ornella F, Emanuela M, Lacopo S, et al. The MDR phenotype is associated with the expression of COX-2 and iNOS in a human hepatocellular carcinoma cell line. Hepatology. 2002;35(4):843–852.
20. Hua S, Shoufeng Z, Yan W, et al. COX-2 contributes to P-glycoprotein-mediated multidrug resistance via phosphorylation of c-Jun atSer63/73 in colorectal cancer. Carcinogenesis. 2011;32(5):667–675.
21. Xulong Z, Weihua X, Lihua W, Zhigang T, Jian Z. Deactivation of signal transducer and activator of transcription 3 reverses chemotherapeutics resistance of leukemia cells via down-regulating P-gp. PLoS One. 2011;6(6):e20965.